Article
Clinical Neurology
Giovanni D'Andrea, Antonina Gucciardi, Giuseppe Giordano, Gennaro Bussone, Alberta Leon
Summary: The study aimed to investigate the role of arginine metabolism in chronic migraine. Results revealed that chronic migraine patients had lower plasma levels of arginine, significantly elevated levels of ornithine, ADMA, and NMMA, while levels of citrulline and SDMA were within normal range.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Jack D. Schim, Carlton Anderson, Elizabeth Brunner, Joe Hirman, Annette Ogbru, Roger Cady, Lora McGill
Summary: This study developed a multivariable model to predict factors affecting the second-dose response to eptinezumab treatment in patients with migraine who initially had a suboptimal response. The results showed that for patients with an unsatisfactory first-dose response, the second dose still had a significant impact on their treatment outcomes, although the response rate was not very high.
Review
Clinical Neurology
Giovanni D'Andrea, Antonina Gucciardi, Alberta Leon
Summary: The pathogenesis of primary headaches, such as migraine and cluster headache, is still debated. This review discusses the possible role of tyrosine and tryptophan metabolism in these conditions, emphasizing neurotransmitter and neuromodulator abnormalities. The study finds important abnormalities in tyrosine-related metabolites in chronic migraine patients, and significantly lower plasma tryptamine levels in both chronic migraine and chronic tension-type headache patients.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Yasuhiko Matsumori, Miki Ishida, Katsuhiro Iba, Byung-Kun Kim, Xiaoping Ning, Masami Nakai, Nobuyuki Koga
Summary: This study evaluated the impact of fremanezumab on the quality of life (QoL) of Japanese/Korean patients with chronic or episodic migraine. The results showed that patients receiving fremanezumab experienced significant improvements in their QoL after 12 weeks of treatment.
Article
Clinical Neurology
Stephen D. Silberstein, Joshua M. Cohen, Ronghua Yang, Sanjay K. Gandhi, Evelyn Du, Adelene E. Jann, Michael J. Marmura
Summary: Responders to fremanezumab treatment demonstrated clinically meaningful improvements in reducing monthly migraine days, acute headache medication use, headache-related disability, and health-related quality of life. The magnitude of improvements in efficacy outcomes was far greater in responders compared to the overall trial population.
JOURNAL OF HEADACHE AND PAIN
(2021)
Review
Clinical Neurology
Qinghui Wang, Shuangmei Wang, Yi Zhu, Fei Lin
Summary: This meta-analysis evaluated the clinical efficacy and safety of rimegepant for the treatment of migraine in adult patients. The results showed that rimegepant had better clinical response compared to placebo, with no significant difference in adverse events.
FRONTIERS IN NEUROLOGY
(2023)
Article
Clinical Neurology
Jakub Jedynak, Eric Eross, Astrid Gendolla, Mallikarjuna Rettiganti, Virginia L. Stauffer
Summary: This study showed that treatment with galcanezumab significantly reduced migraine headache days/month, maintained remission status at subsequent months, and improved quality of life in patients with HFEM compared to placebo.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
Takao Takeshima, Masami Nakai, Yoshiyuki Shibasaki, Miki Ishida, Byung-Kun Kim, Xiaoping Ning, Nobuyuki Koga
Summary: This study aimed to explore the onset of action of fremanezumab in Japanese and Korean migraine patients. The results showed that fremanezumab could reduce the frequency of migraine attacks from the first week after the initial injection, indicating an early onset of action.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Sport Sciences
Sebastian Ludyga, Manuel Hanke, Rahel Leuenberger, Fabienne Bruggisser, Uwe Puehse, Markus Gerber, Sakari Lemola, Andrea Capone-mori, Clemens Keutler, Mark Brotzmann, Peter Weber
Summary: This study investigated the effects of judo training on response inhibition in children born very preterm and children with ADHD. The results showed that judo training significantly improved response inhibition in children born very preterm, but had limited effects on children with ADHD.
MEDICINE & SCIENCE IN SPORTS & EXERCISE
(2023)
Article
Medicine, General & Internal
David Rosmarin, Thierry Passeron, Amit G. G. Pandya, Pearl Grimes, John E. E. Harris, Seemal R. R. Desai, Mark Lebwohl, Mireille Ruer-Mulard, Julien Seneschal, Albert Wolkerstorfer, Deanna Kornacki, Kang Sun, Kathleen Butler, Khaled Ezzedine
Summary: In two phase 3 trials, ruxolitinib cream showed greater repigmentation of vitiligo lesions compared to a vehicle control. However, it was associated with acne and pruritus at the application site.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Gil Yosipovitch, Nicholas Mollanazar, Sonja Staender, Shawn G. Kwatra, Brian S. Kim, Elizabeth Laws, Leda P. Mannent, Nikhil Amin, Bolanle Akinlade, Heribert W. Staudinger, Naimish Patel, George D. Yancopoulos, David M. Weinreich, Sheldon Wang, Genming Shi, Ashish Bansal, John T. O'Malley
Summary: Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely itchy nodules. The use of Dupilumab, a monoclonal antibody, has been shown to effectively improve itch and skin lesions in patients with PN.
Letter
Medicine, General & Internal
Josephine C. Janssen, Evalyn E. A. P. Mulder, Astrid A. M. van der Veldt, David Rosmarin, Deanna Kornacki, Khaled Ezzedine
Summary: The study reports that ruxolitinib cream is effective for repigmentation in vitiligo patients, while caution should be taken regarding potential adverse events and long-term effects.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Behavioral Sciences
Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Noboru Imai, Yasuhiko Matsumori, Yoshihisa Tatsuoka, Yotaro Numachi, Ryuji Yoshida, Cheng Peng, Daniel D. Mikol, Gabriel Paiva da Silva Lima, Sunfa Cheng
Summary: In two 24-week migraine prevention studies, erenumab demonstrated significant reduction in migraine frequency compared to placebo, with efficacy observed as early as the first 4 weeks of treatment initiation.
BRAIN AND BEHAVIOR
(2022)
Article
Clinical Neurology
Timothy R. Smith, Egilius L. H. Spierings, Roger Cady, Joe Hirman, Barbara Schaeffler, Vivienne Shen, Bjorn Sperling, Thomas Brevig, Mette Krog Josiassen, Elizabeth Brunner, Loan Honeywell, Lahar Mehta
Summary: The study evaluated the safety and tolerability of the humanized anti-CGRP monoclonal antibody eptinezumab in patients with migraine across five large-scale clinical trials. The results showed a favorable safety and tolerability profile of eptinezumab in adults with migraine, with most adverse events being mild or moderate in severity.
JOURNAL OF HEADACHE AND PAIN
(2021)
Review
Neurosciences
Peiwei Hong, Yao Liu, Yang Wan, Hai Xiong, Yanming Xu
Summary: This study conducted a systematic review and meta-analysis to investigate the efficacy and safety of transcranial direct current stimulation (tDCS) for migraine treatment. The results showed that tDCS activated or inhibited specific brain areas could reduce the number of migraine days per month in patients with migraine. tDCS was found to be an effective, preventive, and safe treatment option for migraine.
CNS NEUROSCIENCE & THERAPEUTICS
(2022)